A new study shows a person’s insurance status and where they live often impact their access to multi-modality mesothelioma treatment. This can have an impact on their survival. Researchers at the University of Miami Sylvester Comprehensive Cancer Center conducted the new study. They shared their findings at the recent virtual world conference of the International Association for the Study of Lung Cancer. The study found that access to multi-modality mesothelioma treatment was more common in patients with private insurance or Medicare. It was also more common among those who lived closer to larger medical centers. People who lived further out or who did not have insurance often did not receive the treatments that offer the best odds of mesothelioma survival. … Continue reading Access to Multi-Modality Mesothelioma Treatment Limited for Uninsured & Rural Residents
A newly published study says a localized form of chemotherapy called HITHOC for pleural mesothelioma is “safe, feasible, and effective.” Researchers from Italy’s University of Pisa conducted the study. They did a thorough review of the medical literature on the procedure since 1994. They conclude that HITHOC for pleural mesothelioma after surgery keeps tumors in check and improves survival. The downside is that there is not enough standardization in how doctors use the procedure. How HITHOC for Pleural Mesothelioma Works HITHOC stands for hyperthermic intrathoracic chemotherapy. Standard mesothelioma chemotherapy enters the whole body at once through the bloodstream. That is one reason that many mesothelioma patients on chemotherapy have side effects like nausea and low white blood cell counts. HITHOC … Continue reading HITHOC for Pleural Mesothelioma: “Safe, Feasible and Effective”
TTFields and chemotherapy offer one of the most potent combinations against malignant mesothelioma tumors. Now a new study reveals why they work so well together. Tumor Treating Fields (TTFields) are low intensity, intermediate frequency, alternating electric fields. They are delivered into the chest of mesothelioma patients with a vest-like device marketed under the brand name Optune Lua. In 2019, a combination of TTFields and chemotherapy became the first new FDA-approved treatment for mesothelioma in 15 years. Now, a new report in the journal Lung Cancer sheds light on the synergy between the two modes of mesothelioma treatment. Combating Cancer with Electrical Currents The Tumor Treating Fields approach was created by Jersey-based Novocure. The technology uses electrical fields to destabilize critical … Continue reading Study Reveals How TTFields and Chemotherapy Fight Mesothelioma
A new published study suggests that peritoneal mesothelioma patients treated at academic medical centers survive much longer than those who get their care at community hospitals. The study was conducted by Harvard Medical School researchers at Brigham and Women’s Hospital in Boston. Peritoneal mesothelioma is a rare and aggressive cancer of abdominal membranes. There is no known cure. The new study compared outcomes and survival among more than 2,600 mesothelioma patients. Patients were treated at high-volume academic hospitals or community cancer centers. The results suggest that academic medical centers consistently provide more advanced and potentially life-extending care for this complex cancer. Experience is Critical for Mesothelioma Care Malignant mesothelioma is the name for cancers that occur on internal membranes. It … Continue reading Academic Medical Centers Extend Peritoneal Mesothelioma Survival
A protein involved in the inflammatory process could impact how patients respond to drug therapies for mesothelioma. The news comes from researchers at Fox Chase Cancer Center in Philadelphia. The team led by Joseph Testa, PhD, recently released a study of a protein called RIPK3 and its role in malignant mesothelioma. Their research showed that people with little or no expression of RIPK3 were less sensitive to drug therapies for mesothelioma. Turning that gene back on might make tumor cells more responsive. The finding could lead to new, more powerful ways to treat this aggressive cancer. RIPK3, Mesothelioma, and Inflammation Mesothelioma is a rare but fast-growing form of cancer that comes from asbestos exposure. Tumors grow on the tissue that … Continue reading Inflammation Protein May Impact Drug Therapies for Mesothelioma
A comparison of chemotherapy alone versus surgery-based tri-modality treatment for mesothelioma shows patients who take the more aggressive path tend to live much longer. Malignant pleural mesothelioma is a rare cancer with a poor prognosis. Many patients die within a year of diagnosis. Chemotherapy is the most common treatment. But chemotherapy alone is rarely enough to stop this aggressive cancer. Tri-modality mesothelioma treatment combines several different types of therapies. The goal is to attack mesothelioma from different angles. Now, a new study suggests that patients who go this route triple their survival over those who choose more conservative treatment. Surgery-Based Tri-Modality Mesothelioma Treatment Pleural mesothelioma is a fast-growing malignancy on the lining around the lungs. It is almost always caused … Continue reading Tri-modality Mesothelioma Treatment Triples Survival Time in New Study
The best mesothelioma surgery is the one the patient can tolerate with the fewest serious side effects. That’s according to a new study from MD Anderson researchers. Their goal was to help settle the ongoing debate over which type of pleural mesothelioma surgery is most effective. Both EPP and P/D surgery are major operations. But one causes much more serious side effects than the other. So how do doctors and patients decide on the best mesothelioma surgery for their case? The new research suggests there may not be a definitive answer. Debate Over the Best Mesothelioma Surgery Pleural mesothelioma is an asbestos-linked cancer of the membrane around the lungs. During EPP (extrapleural pneumonectomy) surgery, doctors remove this membrane, any other … Continue reading Study Asks What is the Best Mesothelioma Surgery?
A mesothelioma treatment called NIPEC may help people with peritoneal mesothelioma live longer than expected. In some cases, much longer. A recent study of 74 peritoneal mesothelioma patients showed a combination of cytoreductive surgery (CRS), HIPEC, and NIPEC works better than CRS/HIPEC alone. The study comes from one of the country’s foremost medical authorities on peritoneal mesothelioma. Dr. Paul Sugarbaker runs the Peritoneal Surface Malignancy Program at Washington Cancer Institute in Washington, DC. Last year, Dr. Sugarbaker released results of a small study on NIPEC treatment for mesothelioma. Although that study included only six patients, the results were impressive enough to warrant further study. This year’s larger NIPEC study is even more promising for people fighting mesothelioma. Similarities and DIfferences … Continue reading NIPEC Treatment: Is This the Key to Long-Term Mesothelioma Survival?
A Canadian study suggests that triple-modality therapy with radiotherapy, immunotherapy, and surgery may extend the lives of people with malignant pleural mesothelioma. Pleural mesothelioma is an intractable cancer with a poor prognosis. It mainly affects people who have lived or worked around asbestos. There is no cure for mesothelioma. People who have the best mesothelioma outcomes usually have a combination of treatments. Now, scientists at Toronto General Hospital’s Research Institute say a triple-modality therapy they tested in mice might have the power to extend human lives, too. Multi-modal Mesothelioma Treatment Pleural mesothelioma is a fast-growing cancer that starts on the membrane around the lungs. Many mesothelioma patients die less than a year after diagnosis. There is no single accepted treatment … Continue reading Triple-Modality Therapy May Improve Mesothelioma Outcomes, Study Suggests
Dutch researchers say administering maintenance therapy with gemcitabine after chemotherapy may help mesothelioma patients live longer than supportive care alone. Gemcitabine is an antimetabolite sold under the brand name Gemzar. Oncologists use it to treat several other types of cancer. When cancer cells absorb gemcitabine, they can no longer divide into new cancer cells. Most mesothelioma patients have chemotherapy as their first-line treatment. If they are healthy enough, they may also have mesothelioma surgery. A maintenance therapy is a treatment that follows the main treatment. It is an effort to maintain the effects of the treatment. The new Dutch study shows gemcitabine may be a safe and effective choice for maintenance therapy. What Does Maintenance Therapy Mean? Right now, there … Continue reading Maintenance Therapy with Gemcitabine Extends Mesothelioma Survival in Dutch Study